Revolution Medicines, Inc. announced it has received U.S. Food and Drug Administration (FDA) approval for its drug, RASONQUE™ (daraxonrasib). The approval is for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.
Key Details
- Product Approval: RASONQUE™ (daraxonrasib) was approved on August 26, 2026, based on data from the RASolute 302 Phase 3 clinical trial.
- Indication: The drug is for adult patients with metastatic pancreatic adenocarcinoma who have had prior systemic therapy or are not candidates for multiagent systemic therapy.
- Pricing & Availability: RASONQUE™ is now available for prescription in the U.S. with a wholesale acquisition cost of $39,800 for a 30-day supply.